Mechanistic Pharmacokinetic/Pharmacodynamic Modeling in Support of a Patient-Convenient, Longer Dosing Interval for Carfilzomib, a Covalent Inhibitor of the Proteasome-Reference-Cited by-同舟云学术

Mechanistic Pharmacokinetic/Pharmacodynamic Modeling in Support of a Patient-Convenient, Longer Dosing Interval for Carfilzomib, a Covalent Inhibitor of the Proteasome

Published:2023-04-18 Issue:5 Volume:62 Page:779-788
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Yago Marc R.,Mehta Khamir,Bose Maitreyee,Bhagwat Sharvari,Chopra Vivek S.,Dutta Sandeep,Upreti Vijay V.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40262-023-01242-6.pdf

Reference26 articles.

1. Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017;36(4):561–84. https://doi.org/10.1007/s10555-017-9707-8.

2. Ito S. Proteasome inhibitors for the treatment of multiple myeloma. Cancers (Basel). 2020. https://doi.org/10.3390/cancers12020265.

3. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–73. https://doi.org/10.1038/sj.leu.2404284.

4. Kyprolis (carfilzomib) [US prescribing information]. Thousand Oaks: Amgen, Inc.; 2021.

5. Nandi D, Jiang H, Monaco JJ. Identification of MECL-1 (LMP-10) as the third IFN-gamma-inducible proteasome subunit. J Immunol. 1996;156(7):2361–4.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comparative Clinical Pharmacology Analysis of FDA‐Approved Targeted Covalent Inhibitors vs. Reversible Inhibitors in Oncology;Clinical Pharmacology & Therapeutics;2024-07-28

2. Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma;Targeted Oncology;2023-08-26